We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Strong Growth Forecast for Chinese Medical X-Ray Equipment Market

By HospiMedica International staff writers
Posted on 23 Apr 2009
A new market report predicts that the Chinese market for X-ray equipment will reach US$873.0 million by 2012, representing a forecast compound annual growth rate (CAGR) of 9.3%. More...
China's strong economic growth and increased expenditure on public healthcare, combined with the transition from analogue to digital systems, are the two main driving forces.

"The demand for low-end X-ray equipment, such as analogue general radiography, will remain fairly stable over the next few years because the Chinese government will keep investing in rural healthcare, which often lacks basic medical equipment. However, there is tremendous demand for high-end X-ray equipment, especially mobile C-arms and digital radiography," said Owen Tang, a Shanghai-based analyst from InMedica (Wellingborough, UK), an international market research company. "In fact, shipments of digital radiography systems [flat panel detector (FPD) and charged coupled device (CCD)] in China are forecast to almost triple over the period 2007 to 2012."

Multinational companies play a key role in China's high-end X-ray equipment market, including cardiovascular, fluoroscopy, mobile C-arm, and digital radiography. For example, more than 80% of the digital radiography market is served by multinational suppliers. The third-level hospitals have strict requirements for X-ray equipment and the local manufacturers find it hard to compete. The local manufacturers of digital radiography systems, such as Beijing Wandong and Beijing Zhongke Meilun, chiefly compete in the low-end of the market with systems priced under $100,000. These are well suited to China's any second level hospitals.

Distributors play a key role in the Chinese X-ray equipment market, according to InMedica analysts, as Chinese-style customer relationships are extremely important. It is estimated that more than 85% of equipment sales are through distributors.

InMedica is the medical electronics research division of IMS Research, a specialist supplier of market research and consultancy services on a wide range of global electronics markets. The company, headquartered in Wellingborough, UK, is supported by offices in Austin, TX, USA, and Shanghai, China. InMedica publishes research on professional point-of-care markets, such as ultrasound and X-ray equipment; consumer medical devices such as blood-pressure monitors and heart-rate monitors, and a wide range of other medical devices, including patient monitors, aesthetic devices, and diagnostic ophthalmology equipment.

Related Links:
InMedica


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Monitor/Defibrillator
Zenix
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.